Alpha-Fetoprotein (AFP), Spinal Fluid
Use
The Alpha-Fetoprotein (AFP) test in spinal fluid is useful for diagnosing central nervous system (CNS) germinomas and meningeal carcinomatosis. It is particularly helpful in evaluating the presence of germ-cell tumors in the CNS when used alongside cerebrospinal fluid (CSF) beta-human chorionic gonadotropin measurement. This test is also a supplement to CSF cytologic analysis, providing additional diagnostic information in specific clinical settings.
Special Instructions
Not provided.
Limitations
Malignancy may occur without an elevation of alpha-fetoprotein in cerebrospinal fluid. It is suggested to measure beta-human chorionic gonadotropin to improve sensitivity for detection. Values obtained with different assay methods or kits may vary and are not interchangeable. Test results alone cannot be used as absolute evidence for the presence or absence of malignant disease. In rare cases, certain individuals may develop antibodies such as human anti-mouse antibodies that can cause interference in some immunoassays, necessitating caution in result interpretation.
New York Approved
Methodology
Immunoassay (Immunoenzymatic Assay)
Biomarkers
Alpha-Fetoprotein
Protein
LOINC Codes
- 1833-3 - AFP CSF-mCnc
- 1833-3 - AFP CSF-mCnc
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
1 mL
Minimum Volume
0.5 mL
Container
Sterile vial
Collection Instructions
Preferred vial: number 1. Acceptable: any vial.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 7 days |
| Frozen | 7 days |